$1.63
Lexicon Pharmaceuticals is a biotechnology business based in the US. Lexicon Pharmaceuticals shares (LXRX) are listed on the NASDAQ and all prices are listed in US Dollars. Lexicon Pharmaceuticals employs 285 staff and has a trailing 12-month revenue of around $3.6 million.
Our top picks for where to buy Lexicon Pharmaceuticals stock
How to buy Lexicon Pharmaceuticals stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – LXRX. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Lexicon Pharmaceuticals stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Lexicon Pharmaceuticals stock price (NASDAQ: LXRX)
Use our graph to track the performance of LXRX stocks over time.Lexicon Pharmaceuticals shares at a glance
Latest market close | $1.61 |
---|---|
52-week range | $0.92 - $3.73 |
50-day moving average | $1.84 |
200-day moving average | $1.82 |
Wall St. target price | $6.20 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | $-0.78 |
Is it a good time to buy Lexicon Pharmaceuticals stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Lexicon Pharmaceuticals price performance over time
Historical closes compared with the close of $1.61 from 2024-09-03
1 week (2024-08-29) | -10.56% |
---|---|
1 month (2024-08-05) | 6.27% |
3 months (2024-06-05) | -17.01% |
6 months (2024-03-05) | -28.44% |
1 year (2023-09-05) | -1.83% |
---|---|
2 years (2022-09-02) | -40.81% |
3 years (2021-09-03) | 4.97 |
5 years (2019-09-05) | 24.81% |
Lexicon Pharmaceuticals financials
Revenue TTM | $3.6 million |
---|---|
Gross profit TTM | $-52,677,000 |
Return on assets TTM | -35.69% |
Return on equity TTM | -94.81% |
Profit margin | 0% |
Book value | $0.66 |
Market Capitalization | $625.4 million |
TTM: trailing 12 months
Lexicon Pharmaceuticals share dividends
We're not expecting Lexicon Pharmaceuticals to pay a dividend over the next 12 months.
Have Lexicon Pharmaceuticals's shares ever split?
Lexicon Pharmaceuticals's shares were split on a 1:7 basis on 20 May 2015. So if you had owned 7 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Lexicon Pharmaceuticals shares – just the quantity. However, indirectly, the new 600% higher share price could have impacted the market appetite for Lexicon Pharmaceuticals shares which in turn could have impacted Lexicon Pharmaceuticals's share price.
Lexicon Pharmaceuticals share price volatility
Over the last 12 months, Lexicon Pharmaceuticals's shares have ranged in value from as little as $0.92 up to $3.73. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Lexicon Pharmaceuticals's is 1.357. This would suggest that Lexicon Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Lexicon Pharmaceuticals overview
Lexicon Pharmaceuticals, Inc. , a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas. .
Frequently asked questions
What percentage of Lexicon Pharmaceuticals is owned by insiders or institutions?Currently 1.148% of Lexicon Pharmaceuticals shares are held by insiders and 79.239% by institutions. How many people work for Lexicon Pharmaceuticals?
Latest data suggests 285 work at Lexicon Pharmaceuticals. When does the fiscal year end for Lexicon Pharmaceuticals?
Lexicon Pharmaceuticals's fiscal year ends in December. Where is Lexicon Pharmaceuticals based?
Lexicon Pharmaceuticals's address is: 2445 Technology Forest Boulevard, The Woodlands, TX, United States, 77381 What is Lexicon Pharmaceuticals's ISIN number?
Lexicon Pharmaceuticals's international securities identification number is: US5288723027 What is Lexicon Pharmaceuticals's CUSIP number?
Lexicon Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 528872104
More guides on Finder
-
Best options trading platforms of 2024
SoFi, Robinhood, Tastytrade, Webull, Interactive Brokers, E*TRADE, eToro and others top our list for the best options trading platforms.
-
What is a covered call?
A covered call is an options trading strategy that allows you to generate income from stocks you already own.
-
6 stocks like Nvidia you need to consider
Advanced Micro Devices (AMD), Intel Corporation (INTC) and Qualcomm Inc (QCOM) are top stocks like Nvidia. See our full list here.
-
Frec review 2024: Low-cost direct indexing and individual stock trading
A deep dive into the highlights and limitations of Frec.
-
Public vs. Robinhood
Compare pros, cons, research tools and reviews for these two trading platforms.
-
How to invest in the S&P 500 in 2024
What you need to know about investing in the leading indicator for the overall US stock market.
-
Streitwise review
An online REIT with low fees, consistent dividends and a stable portfolio, but a brief track record.
-
Interactive Brokers review 2024: Tailored trading and investing
Interactive Brokers has advanced charting tools but a high net requirement to qualify.
-
Top 15 tech stocks to invest in for 2024
Discover the top tech stocks poised to lead innovation and offer substantial growth opportunities.
-
Wealthfront review: Low-cost automated and DIY investing
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.
Ask a question